Literature DB >> 29671244

Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK.

Rachelle Abouchedid1, Thea Gilks2, Paul I Dargan3,4, John R H Archer3,4, David M Wood3,4.   

Abstract

INTRODUCTION: There has been increasing interest in the availability of non-prescription benzodiazepines and their sale as new psychoactive substances. We wanted to determine UK availability from Internet suppliers and motivations for use of three benzodiazepines (diclazepam, flubromazepam, and pyrazolam).
METHODS: In November 2014 and March 2016, using the European Monitoring Centre for Drugs and Drug Addiction Snapshot Methodology, Internet search engines ( google.co.uk , uk. yahoo.com and ask.com.uk ) were searched using the terms 'buy diclazepam', 'buy flubromazepam' and 'buy pyrazolam'. Threads from drug-user forums ( bluelight.org , drugs-forum.com , erowid.org , legalhighsforum.com ) were analysed using a general inductive approach. Data were converted into price per gram/pellet to allow cost comparisons and to determine motivations for use.
RESULTS: There was an increase in websites selling these benzodiazepines between 2014 and 2016: diclazepam (49 in 2014 to 55 in 2016), pyrazolam (33 to 35), and flubromazepam (39 to 45). Thirty-eight (63.3%) sites were based in the UK/Europe. Drugs were sold as pellets (49 websites, 81.7%), powder (19, 31.7%), and blotters (1, 1.7%). Pill forms were not available, and one (1.7%) website sold diclazepam/flubromazepam in liquid form. The cost reduced with increasing purchase quantities. Main motivations for use included anxiolysis, management of benzodiazepine withdrawal, sedation/sleep aid, and management of stimulant withdrawal.
CONCLUSIONS: These three benzodiazepines are widely available online, most commonly as pellets, and are (mis)used for a number of reasons. This study could be used to support triangulation of data from other sources to inform harm minimisation strategies.

Entities:  

Keywords:  Benzodiazepines; Diclazepam; Flubromazepam; New psychoactive substances; Pyrazolam

Mesh:

Substances:

Year:  2018        PMID: 29671244      PMCID: PMC5962469          DOI: 10.1007/s13181-018-0659-3

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  13 in total

1.  Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project.

Authors:  Paolo Deluca; Zoe Davey; Ornella Corazza; Lucia Di Furia; Magi Farre; Liv Holmefjord Flesland; Miia Mannonen; Aino Majava; Teuvo Peltoniemi; Manuela Pasinetti; Cinzia Pezzolesi; Norbert Scherbaum; Holger Siemann; Arvid Skutle; Marta Torrens; Peer van der Kreeft; Erik Iversen; Fabrizio Schifano
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-07-27       Impact factor: 5.067

2.  First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam.

Authors:  Paul I Dargan; Susannah Davies; Malgorzata Puchnarewicz; Atholl Johnston; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2012-07-29       Impact factor: 2.953

3.  Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.

Authors:  Bjoern Moosmann; Philippe Bisel; Volker Auwärter
Journal:  Drug Test Anal       Date:  2014-03-06       Impact factor: 3.345

Review 4.  Phenazepam: the drug that came in from the cold.

Authors:  Peter D Maskell; Giorgia De Paoli; L Nitin Seetohul; Derrick J Pounder
Journal:  J Forensic Leg Med       Date:  2012-01-15       Impact factor: 1.614

5.  Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics.

Authors:  Bjoern Moosmann; Laura M Huppertz; Melanie Hutter; Armin Buchwald; Sascha Ferlaino; Volker Auwärter
Journal:  J Mass Spectrom       Date:  2013-11       Impact factor: 1.982

6.  Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines.

Authors:  John R M Caplehorn; Olaf H Drummer
Journal:  Aust N Z J Public Health       Date:  2002-08       Impact factor: 2.939

7.  An Internet snapshot study to compare the international availability of the novel psychoactive substance methiopropamine.

Authors:  A-E Vermette-Marcotte; P I Dargan; J R H Archer; S Gosselin; D M Wood
Journal:  Clin Toxicol (Phila)       Date:  2014-08       Impact factor: 4.467

8.  Benzodiazepines: a summary of pharmacokinetic properties.

Authors:  D J Greenblatt; R I Shader; M Divoll; J S Harmatz
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

9.  Using internet snapshot surveys to enhance our understanding of the availability of the novel psychoactive substance 4-methylaminorex and 4,4'-dimethylaminorex.

Authors:  Hisham Nizar; Paul I Dargan; David M Wood
Journal:  J Med Toxicol       Date:  2015-03

10.  6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.

Authors:  J B Hester; P Von Voigtlander
Journal:  J Med Chem       Date:  1979-11       Impact factor: 7.446

View more
  3 in total

Review 1.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

2.  The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents.

Authors:  Eunchong Hong; Sun Mi Gu; Jin Mook Kim; Kyung Sik Yoon; Jin-Moo Lee; Young-Hoon Kim; Soo Kyung Suh; Dohyun Lee; Heejong Eom; Jaesuk Yun; Hye Jin Cha
Journal:  Toxicol Res (Camb)       Date:  2022-07-08       Impact factor: 2.680

Review 3.  Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.

Authors:  Pietro Brunetti; Raffaele Giorgetti; Adriano Tagliabracci; Marilyn A Huestis; Francesco Paolo Busardò
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.